The future of predictive models in radiation oncology: from extensive data mining to reliable modeling of the results

Related Experiment Video

Updated: May 13, 2026

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Vincenzo Valentini, Nicola Dinapoli, Andrea Damiani

    Future Oncology (London, England)
    |March 9, 2013
    PubMed
    Abstract

    No abstract available in PubMed .

    Related Experiment Videos

    Last Updated: May 13, 2026

    Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
    04:09

    Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

    Published on: October 10, 2018

    Related Concept Videos

    Cancer Survival Analysis01:21

    Cancer Survival Analysis

    Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
    Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

    Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

    Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
    The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...

    Articles linked to this work by shared authors, journal, and citation graph.

    Enhancing Decision-Making in Pediatric Radiotherapy: Internal Validation and Expansion of the M.A.P.-RT Schedule for Sedation Need Prediction and Identification of Psychological Support Needs in a Prospective Cohort of 268 Pediatric Patients.

    Children (Basel, Switzerland)·2026

    In vivo dosimetry using an electronic portal imaging device for pediatric myeloablative Total body irradiation with volumetric modulated arc therapy.

    Physics and imaging in radiation oncology·2026

    OCTN1 variants shape innate immunity and predict individual response to anti-TNFα in ulcerative colitis patients: An exploratory study.

    Inflammatory bowel diseases·2026

    Inguinal CTV contouring in anal cancer: comparative validation of inguinal lymph nodes contouring guidelines and implications for consensus.

    Clinical and translational radiation oncology·2026

    Managing unplanned radiotherapy interruptions in Italy: results from an AIRO survey.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026

    Federated learning in inflammatory bowel disease: The future of privacy-preserving Artificial Intelligence.

    Best practice & research. Clinical gastroenterology·2025

    Durvalumab plus etoposide-carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E).

    Future oncology (London, England)·2026

    Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092).

    Future oncology (London, England)·2026

    Real-world effectiveness of first-line chemoimmunotherapy versus chemotherapy in older adults with extensive-stage small cell lung cancer: an inverse probability treatment weighted analysis.

    Future oncology (London, England)·2026

    First-line osimertinib with or without chemotherapy for EGFR-mutant advanced NSCLC in China: a cost-effectiveness analysis.

    Future oncology (London, England)·2026

    TroFuse-032 study design: pembrolizumab plus sacituzumab tirumotecan or chemotherapy followed by pembrolizumab plus chemotherapy as neoadjuvant therapy for early-stage, triple-negative breast cancer or HR-low+/HER2- breast cancer.

    Future oncology (London, England)·2026

    Interleukin-6 as a prognostic biomarker in hepatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis.

    Future oncology (London, England)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us